Vivodyne Announces $38 Million Seed Financing Led By Khosla Ventures To Develop Lab-Grown Human Organs

Nov 22, 2023•about 2 years ago

Amount Raised

$38 Million

Round Type

seed

BrisbaneBiotechnology

Investors

Bison VenturesMbx CapitalCs VenturesKairos VenturesKhosla Ventures

Description

Vivodyne, a biotech that discovers and develops more effective drugs by testing them on lab-grown human organs, today announced the close of $38 million in total seed financing, led by Khosla Ventures, with participation from Kairos Ventures, CS Ventures, MBX Capital, and Bison Ventures.

Company Information

Company

Vivodyne

Location

Brisbane, California, United States

About

Vivodyne is a biotechnology company that accelerates the development of more effective medicines by testing on thousands of lifelike, lab-grown human organ tissues at a time. Robots are used to grow and experiment on lab-grown human organs at massive scale, creating datasets of unparalleled realism and breadth to power a predictive AI platform technology. Vivodyne was founded by University of Pennsylvania bioengineers Andrei Georgescu and Dan Huh.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends